US National Institutes of Health
We have successfully entered into two collaborative research and development agreements with the US National Institute of Child Health and Human Development, a remarkable accomplishment for a small European pharmaceutical company. The first, signed in 2001 relates to the clinical development of CDB-2914 (ella® / ellaOne®, UPA) and to other developments in contraception. The second, signed in 2006, covers the development of HRA compounds for Cushing's syndrome treatment. Both agreements have been renewed periodically.
The Population Council
The Population Council is an international, not-for-profit, non-governmental organization that conducts biomedical, social science, and public health research. HRA Pharma has been working with the Council on various projects to develop innovative contraceptive technologies. One of these projects involves HRA Pharma's product UPA, a first-in-class, orally active selective progesterone receptor modulator being developed to provide continuous contraception via novel delivery systems.
Gynuity Health Projects
Gynuity Health Projects, a non-governmental organization that works globally to ensure that reproductive health technologies are widely available and provided in the context of high quality services with a focus on resource-poor environments and underserved populations. HRA Pharma has been working with Gynuity on a research and regulatory strategy for the use of pericoital levonorgestrel as an ongoing contraceptive method for women who have infrequent intercourse.
Institut Gustave Roussy (France)
We have research agreements with Institut Gustave Roussy for the evaluation of the impact of mitotane concentration in lipoproteins on tumor response in the treatment of advanced adrenocortical carcinoma.
University of Sheffield (UK)
We have several ongoing clinical projects in collaboration with the University of Sheffield in the evaluation of metyrapone effects in Cushing’s syndrome and adrenal tumors.
Universitá di Torino (U.N.I.T.O., Italy)
We have a cooperation agreement with the Universitá di Torino the sponsor of the ADIUVO trial Efficacy of adjuvant mitotane treatment in prolonging recurrence-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence which is an ongoing international study.
The European network for the study of adrenal tumors (ENS@T)
ENS@T was founded in 2002 by putting together three already existing national adrenal networks all dedicated to the study of adrenal tumors. In 2009, ENS@T became a membership-based society with statutes and by-laws. HRA Pharma has supported ENS@T on several projects including the set-up of a registry for adrenocortical carcinoma (ACC) and the support of clinical trials such as FIRM ACT. We have initiated in conjunction with ENS@T the ACC awards since 2012. Every year, two awards, one for a preclinical and one for clinical research, are given for innovative work accomplished in the field of adrenocortical cancer.